Table 2.
Characteristics of the included trials.
| Study | Country | Study design | Pts/eyes (n) | Mean age (year) | Gender (M/F) | Follow-up (mo) | Preoperative BCVA | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E | E+I | E | E+I | E | E+I | E | E+I | E | E+I | |||
| Kim et al., 2005 [19] | Korea | Retrospective comparative | 17 | 17 | 61.6 (43~78) | 63.5 (48~79) | 7/10 | 12/5 | 11.2 (6~27) | 8.9 (6~11) | 0.71 ± 0.50 | 0.71 ± 0.16 |
| Kwok et al., 2005 [25] | Hong Kong | Retrospective | 15 | 20 | 67.9 ± 8.0 | 63.9 ± 9.3 | 13/2 | 2/18 | 50.2 ± 18.0 | 23.6 ± 5.4 | 0.90 ± 0.293 | 0.652 ± 0.429 |
| Liu and Mori, 2005 [24] | Japan | Retrospective | 20 | 18 | 68.2 ± 6.9 | 69.4 ± 5.7 | 9/11 | 9/9 | >3 months | 0.35 ± 0.26 | 0.44 ± 0.21 | |
| Lee and Kim, 2010 [18] | Korea | Retrospective | 19 | 21 | 65.47 ± 7.66 | 63.43 ± 7.18 | 3/16 | 4/17 | 18.32 ± 12.03 | 18.05 ± 11.81 | 0.67 ± 0.34 | 0.68 ± 0.21 |
| Pournaras et al., 2011 [17] | Switzerland | Retrospective | 15 | 24 | 77.1 ± 6.7 | 73.3 ± 10.6 | 7/8 | 13/11 | 41.9 ± 35.6 | 24.0 ± 12.6 | 0.48 ± 0.22 | 0.58 ± 0.40 |
| Chang et al., 2013 [23] | America | Retrospective | 40 | 40 | 70.5 | 70.1 | — | — | 3 months | 0.44 ± 0.18 | 0.52 ± 0.31 | |
| Oh et al., 2013 [16] | Korea | Retrospective | 23/23 | 20/20 | 64.0 | 65.3 | 10/13 | 7/13 | >12 months | 0.35 ± 0.16 | 0.44 ± 0.21 | |
| Ahn et al., 2014 [22] | Korea | Retrospective | 65/69 | 37/40 | 63.9 ± 11.1 | 64.3 ± 10.0 | 32/37 | 18/22 | >6 months | 0.31 ± 0.21 | 0.38 ± 0.19 | |
E: epiretinal membrane peeling only.
E+I: epiretinal membrane + internal limiting membrane peeling.